RepliCel Announces Material Patent Milestones in Key Markets

AccesswireAug 4, 2022 06:05 ET

DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

AccesswireAug 2, 2022 06:05 ET

CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

AccesswireJul 26, 2022 16:50 ET

Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing

AccesswireJul 26, 2022 06:05 ET

RepliCel Announces Material Patent Milestones

AccesswireJan 10, 2022 06:06 ET

RepliCel Closed Final Tranche of Strategic Investment Commitment

AccesswireDec 21, 2021 17:06 ET